What’s funding like in the longevity market right now?

All funding deals in the longevity market over the last 24 months

Below is the table listing all the deals. You can find our methodology at the end of this page.

If you want a deeper understanding of the market and its current dynamics, get our longevity market report.

Is longevity funding actually healthier now than it was a year ago?

Longevity funding looks healthier today because many more companies are getting financed, although the giant increase in dollars makes the improvement look more dramatic than it really is.

We counted 57 financings in the latest 12 months, up from 38 in the previous period. The number of funded companies rose from 36 to 50, while disclosed capital jumped from $942.2 million to $2.49 billion.

The catch is the typical round. The median financing slipped from $10 million to $9.35 million even as the average climbed from $27.7 million to $49.8 million. Investors are funding more companies, but the huge increase in capital is coming disproportionately from the top end of the market.

So the picture today is fairly clear: access to funding has widened, while the biggest winners can now raise amounts that were much less common one year earlier.

Metric	Latest 12 months	Previous 12 months	Change
Deals	57	38	+50.0%
Unique companies	50	36	+38.9%
Disclosed capital	$2.489B	$942.2M	+164.2%
Median disclosed round	$9.35M	$10.0M	-6.5%
Average disclosed round	$49.8M	$27.7M	+79.6%
Largest round	$700M	$260M	+169.2%
Companies raising multiple times	7	2	+250%

Does longevity funding still look stronger without the mega-rounds?

Longevity funding still looks stronger without the mega-rounds, although the apparent boom becomes much more modest.

Once we remove every round above $50 million, current funding falls to $435.9 million. The previous period produced $356.2 million on the same basis, leaving underlying capital growth at 22.4%.

The top end therefore amplifies the market rather than creating the entire increase. The deal count points the same way: activity rose strongly even before we start discussing Neko Health's $700 million Series C, NewLimit's $435 million Series C or Function Health's $298 million Series B.

Looking only at the $2.49 billion headline would still give readers the wrong impression. A better description is a market with stronger underlying deal activity and an unusually powerful layer of mega-rounds sitting on top of it.

Are more longevity companies getting funded today?

Yes, longevity funding is reaching substantially more companies today, and the increase has been steady enough to look like real market expansion rather than a busy quarter.

We found 50 funded companies in the latest period, compared with 36 before. First financings also rose from 12 to 19, showing that new names are still entering the market rather than all of the extra activity coming from repeat rounds.

The monthly data backs that up. Median deal activity increased from three financings a month to 5.5, and neither comparison period contained a zero-deal month. Current activity is simply running at a higher level.

That broader flow is one of the strongest reasons to call the market healthier. A funding surge concentrated in three or four companies would tell a very different story.

Are investors backing new longevity startups or mostly doubling down on existing winners?

Longevity investors are backing more new startups, but established companies are capturing nearly all of the serious money.

First financings increased, yet their median size fell from $8.9 million to $5 million. Follow-on rounds moved in the opposite direction, with their median rising from $13.85 million to $17 million.

The capital split is even sharper. New-company financings accounted for $138.8 million, while follow-ons generated $2.22 billion. Roughly nine out of every ten disclosed dollars went to companies that had already raised before. When nine of every ten dollars go to companies that raised before, we look at which investors are placing the biggest bets in our report on longevity.

For founders, the practical takeaway is simple. Getting into the market appears easier than a year ago, but the really large commitments are going to companies that have already built some history.

Metric	Latest 12 months	Previous 12 months
First financings	19	12
First-financing share	33.3%	31.6%
First-financing capital	$138.8M	$103.9M
Median first financing	$5.0M	$8.9M
Follow-on financings	36	26
Follow-on capital	$2.223B	$838.3M
Median follow-on	$17.0M	$13.85M

Are longevity funding rounds actually getting bigger?

The biggest longevity rounds are getting much bigger, while ordinary rounds are roughly the same size or slightly smaller.

The deal-size distribution has opened up at both ends. Among financings with usable amounts, 26% were below $5 million, up from 20.6%. At the other end, 20% were at least $50 million, compared with 11.7% previously.

The middle lost ground. Rounds between $5 million and $20 million fell from 50% of known deals to 40%, while the $20 million to $50 million band also became less common.

That explains the strange combination we see now: the median round went down, the average shot up, and total capital exploded. Today's longevity market has more small entry rounds alongside a much larger group of very heavily funded winners.

Where is longevity money moving right now?

Longevity money is moving most clearly toward preventive health platforms, while therapeutics continue to absorb a similarly large share of funding.

Preventive Health Platforms went from 26.3% of deals to 38.6%, putting them level with Longevity Therapeutics by deal count. Their typical round actually became smaller, which tells us the category is broadening beneath its biggest names.

Therapeutics held their ground. They represented 38.6% of current deals and 42.3% of capital, both slightly above the previous period.

Healthy Aging Clinics moved the other way, with their deal share roughly halving. Consumer Longevity Brands also became less common by deal count, even though a few larger financings lifted the typical round.

Category	Current deal share	Previous deal share	Current capital share	Previous capital share	Current median
Longevity Therapeutics	38.6%	36.8%	42.3%	40.0%	$12.6M
Preventive Health Platforms	38.6%	26.3%	46.3%	47.1%	$5.47M
Healthy Aging Clinics	7.0%	13.2%	4.8%	6.9%	$7.0M
Consumer Longevity Brands	7.0%	10.5%	4.7%	3.2%	$28.25M
Diagnostics / Biomarkers	7.0%	5.3%	1.2%	0.5%	$6.85M
Aging Research Platforms	1.8%	7.9%	0.7%	2.3%	$17.0M

Is preventive health really winning more investor attention?

Preventive health is currently the clearest area of expansion in longevity funding because far more companies are getting financed, rather than one giant round carrying the category.

The category produced roughly twice as many deals as in the preceding period. The newer activity stretches well beyond Neko Health and Function Health. Deals roughly doubling in preventive health is a big move; we track how much money went in, quarter by quarter, in our longevity market report.

Ahead Health, for example, raised $6 million and then added another $10 million as it expanded from Switzerland into Germany and the Netherlands. Cent Health launched with roughly $5 million. SONATA raised $7 million, while YouLabs brought in $2.6 million.

Those rounds are far smaller than the category leaders, which is precisely why they are useful. They show investors funding different versions of preventive care across Europe, North America and Asia-Pacific.

The momentum looks fairly broad. Investors are increasingly willing to finance companies that combine diagnostics, longitudinal health data, imaging, biomarkers and clinician-guided prevention, even before those businesses reach major scale.

Are longevity therapeutics being pushed aside by preventive health?

Longevity therapeutics are still one of the market's two main funding engines, and several of the biggest current rounds are moving drug programs closer to patients.

NewLimit raised $435 million as it works toward bringing its first epigenetic-reprogramming medicine into human trials. Corsera Health raised an $80 million Series A alongside the start of Phase 1 dosing for its PCSK9 siRNA program.

Cognito Therapeutics raised $105 million in Series C financing to advance its Alzheimer's program, while Tenpoint Therapeutics raised $85 million of Series B equity around the commercialization of its treatment for presbyopia.

There is plenty happening earlier in development too. Cirrus Therapeutics raised $11 million to move an ocular gene therapy toward IND-enabling studies, and TECregen raised roughly $12.6 million for biologics targeting thymus regeneration.

Preventive health has widened the longevity market lately. Therapeutics, meanwhile, continue to attract deep pools of capital when programs reach meaningful development milestones.

Are investors shifting toward later-stage longevity companies?

Longevity investors are putting far more money into later-stage companies now, even though seed rounds still dominate the number of deals.

Seed represented 54.4% of current financings but only 5.7% of known capital. Series C went from no recorded deals in the previous period to four current financings responsible for more than half of disclosed dollars.

Series A became noticeably thinner. We found six current Series A deals compared with 11 before, cutting its deal share from 28.9% to 10.5%. The median Series A round, however, rose from $15.85 million to $33 million.

Some caution is necessary here because stage disclosure became worse: ten current financings have an unknown stage versus three previously. Even with that limitation, the movement of actual dollars toward Series B, Series C and growth rounds is too large to ignore.

Stage	Current deals	Current deal share	Current capital share	Previous deals	Previous deal share
Seed	31	54.4%	5.7%	18	47.4%
Series A	6	10.5%	9.8%	11	28.9%
Series B	3	5.3%	16.7%	6	15.8%
Series C	4	7.0%	53.8%	0	-
Series D+	2	3.5%	4.7%	0	-
Growth Equity	1	1.8%	4.4%	0	-
Unknown	10	17.5%	4.8%	3	7.9%

Do longevity startups need more proof to raise big money now?

The largest longevity rounds today usually come after investors can point to something concrete: customer adoption, clinical progress, manufacturing readiness or a clear path to commercialization.

Neko Health is a good example on the consumer side. By the time of its $700 million financing, the company reported more than 100,000 completed scans in the UK and Sweden, more than 350,000 registrations or waitlist members, and a 75% same-day rebooking and prepayment rate. The new capital is supporting further expansion, including the U.S. Traction like this comes before the raise, and we weigh who the likely future winners are in our report covering longevity.

Biotech is showing a similar pattern through different milestones. NewLimit's large round came as the company prepared its first reprogramming medicine for human trials and worked through the manufacturing scale-up needed for clinical development. Corsera combined its Series A with the start of Phase 1 dosing.

Investors clearly have not stopped funding very early ideas. Seed deals are still everywhere. The funding bar simply becomes much more visible once a company starts asking for tens or hundreds of millions of dollars.

Are longevity companies raising again faster these days?

Longevity companies appear to be coming back to investors faster, although the historical data is too patchy for a high-confidence market-wide claim.

Among current follow-ons where we could identify a usable earlier round, median spacing was 7.4 months. The comparable figure was 11 months in the previous period.

The sample quality is uneven. We can calculate timing for 19 current follow-ons but only five from the earlier period, so a precise year-on-year conclusion would oversell the evidence.

A second measure points in the same direction. Seven companies raised more than once inside the latest 12-month period, compared with two previously. Where previous round sizes are available, the median observed step-up also rose to 1.87x, although once again the older comparison is based on only five cases.

For now, faster repeat fundraising is a credible pattern worth watching rather than a settled rule of the market.

Is longevity funding becoming less US-centric?

Longevity funding is becoming much more international by deal count, while North America and Europe still control almost all of the large checks.

North America's share of deals fell from 63.2% to 45.6%. Its share of capital barely moved, staying around 56%.

Asia-Pacific moved from 10.5% to 19.3% of financings, with activity across India, China, Singapore and Australia. The Middle East also became visible for the first time in this comparison, reaching 8.8% of deals. Asia-Pacific gaining share of deals is a real shift; we cover what else has changed in the last year in our longevity market report.

The money has not followed at the same speed. Asia-Pacific received only 3.2% of disclosed capital and the Middle East 0.6%.

Europe remains a major funding center, although its numbers are heavily influenced by Sweden. Swedish companies accounted for about $729 million, with Neko responsible for most of that total.

These days, the longevity startup map is clearly widening faster than the capital map.

Are corporate investors playing a bigger role in longevity funding?

Corporate investors are writing much more consequential checks in longevity today, even though they are showing up in a slightly smaller share of deals.

We found seven current financings with a disclosed strategic investor compared with six previously. Because the overall market grew faster, the strategic participation rate actually declined from 15.8% to 12.3%.

The size of those deals changed much more. Median strategic-backed financing rose from about $9.6 million to $33.5 million, and the current group is heavily tilted toward therapeutics.

Juvena Therapeutics illustrates the pattern well. Eli Lilly had already entered a research collaboration with Juvena around muscle health and body composition before participating in its $33.5 million Series B. Juvena's JUV-161 program has since progressed beyond its initial Phase 1 work and into a Phase 1/2 study.

Boehringer Ingelheim Venture Fund led TECregen's financing around thymus-regeneration biologics. Merck Animal Health combined its investment in Rejuvenate Bio with a formal R&D collaboration around gene therapy.

Corporate money currently looks selective and closely tied to programs where the investor has an obvious scientific or commercial reason to care.

Is the longevity investor base getting broader or narrower?

The observable longevity investor base is much broader today, with more new names appearing even as repeat participation becomes less common.

We identified 56 unique disclosed investors in the latest period, compared with 33 previously. Unique disclosed leads increased from 32 to 51.

Only three current investors appeared in more than one financing, compared with seven during the preceding period. RTP Global was the only disclosed current lead to show up twice.

Those figures come with an important limitation: complete syndicates are rarely public. At least one investor is identifiable for about 70% of current deals, but we cannot reconstruct every cap table from public evidence.

Even with that gap, the visible investor pool expanded much faster than the number of funded companies. More firms are taking part in longevity financing now, rather than the growth being carried by the same small group of specialist funds.

What are longevity companies raising money to do now?

Longevity companies are increasingly raising large rounds to move from building something promising toward deploying, commercializing or clinically translating it.

The preventive-health examples are straightforward. Function Health linked its $298 million Series B to continued growth and its Medical Intelligence platform after reaching hundreds of thousands of members and acquiring Ezra. Ahead Health is using new capital to enter additional European markets and add partner clinics. Money earmarked for new markets and partner clinics shows where companies see openings, and we look at the biggest opportunities in our longevity report.

Therapeutics have reached their own version of the same transition. TECregen says its financing will accelerate development of its thymus-regeneration biologics. Cirrus is advancing its lead ocular gene therapy into IND-enabling work. Tenpoint's equity financing arrived alongside preparations to commercialize an approved presbyopia treatment.

We cannot turn this into a market-wide percentage because most financing announcements do not provide structured use-of-funds or comparable milestone data.

Still, as we saw above, the biggest current checks are increasingly attached to execution: entering new countries, scaling delivery, manufacturing clinical material, starting trials or preparing products for the market.

Is longevity funding getting too concentrated?

Longevity funding is more dependent on large rounds today, although the market has not become dramatically more dependent on a single company.

Rounds above $50 million accounted for 82.5% of current disclosed capital, up from at least 62.2% previously.

The biggest deal represented 28.1% of the current total, almost unchanged from 27.6% in the previous period. The top five also stayed remarkably stable, moving from 65.9% to 66.2%.

That combination is unusual. The market now has many more dollars tied up in large rounds, yet concentration at the very top barely changed.

Why? Several companies reached mega-round territory at the same time. Alongside Neko, the current period included NewLimit, Function Health, Lanserhof and Cognito Therapeutics at more than $100 million each.

The dependence on large financing events has clearly increased, while dependence on one single outlier has not.

Is longevity becoming a more mature funding market?

Longevity funding looks more mature today because the market can support both a larger pipeline of new companies and a much deeper pool of capital for businesses that have already proved something.

The median funded company is actually younger than before, falling from roughly four years old to three. Companies receiving their first financing had a median age of about one year.

At the same time, follow-on companies are raising larger typical rounds, late-stage financings are taking most of the money, and companies capable of raising nine-figure rounds are appearing across both preventive health and therapeutics.

That combination is more informative than the raw funding total. Longevity currently has an active formation layer at the bottom and a genuine scale-up layer at the top.

The weaker point is the middle. Series A activity fell sharply, and $5 million to $50 million rounds lost share of the deal-size distribution. Whether that gap persists is one of the most useful things to watch next.

What really changed over the last 12 months?

The biggest change is that longevity funding became broader. More companies raised money, more companies received their first financing, monthly deal activity increased, and the visible investor pool widened.

At the same time, the spectacular increase in total dollars mostly belongs to companies at the top of the market. Removing rounds above $50 million leaves growth of a little over 20%, which is healthy but far removed from the triple-digit headline increase.

New startups are benefiting mainly through access rather than bigger checks. Their typical first financing became smaller, while follow-on companies attracted far more capital and larger median rounds.

Preventive health gained the clearest momentum in company count. Therapeutics remained just as important financially and are increasingly raising money around clinical translation rather than purely early discovery.

Large-round investors currently appear to want more proof. On the consumer side, that can mean adoption and repeat usage. In biotech, it can mean human trials, validated programs, manufacturing readiness or strategic partnerships with pharma.

Longevity has also become more global and more mature without becoming uniformly easier to fund. The strongest description today is a broader market with a more powerful scale-up layer, plus a slightly hollowed-out middle between small early rounds and the biggest financings.